Chemical markers in Origanum vulgare L. from Kumaon Himalayas: a chemosystematic study

The essential oils of four wild growing Origanum vulgare L. (family Lamiaceae) collected from different locations in Kumaon region (Uttarakhand, India) were analysed by capillary GC and GC/MS. The comparative results of O. vulgare L. collected from four different regions showed differences in the chemical constituents of the essential oils. The oil of O. vulgare L. collected from Dhoulchina and Champawat (chemotype I) shows p-cymene (6.7-9.8%), γ-terpinene (12.4-14.0%), thymol (29.7-35.1%) and carvacrol (12.4-20.9%) as major constituents while the oil from Kilbury and Rushi village (chemotype II) shows linalool (6.7-9.7%), bornyl acetate (12.6-16.8%), β-caryophyllene (10.5-13.8%) and germacrene D (6.3-11.3%) as the major constituents. These features highlight the chemosystematics of this genus.     

Amyloid Cross-Seeding: Mechanism,Implication, and Inhibition

Most neurodegenerative diseases such as Alzheimer’s disease, type 2 diabetes, Parkinson’s disease, etc. are caused by inclusions and plaques containing misfolded protein aggregates. These protein aggregates are essentially formed by the interactions of either the same (homologous) or different (heterologous) sequences. Several experimental pieces of evidence have revealed the presence of cross-seeding in amyloid proteins, which results in a multicomponent assembly; however, the molecular and structural details remain less explored. Here, we discuss the amyloid proteins and the cross-seeding phenomena in detail. Data suggest that targeting the common epitope of the interacting amyloid proteins may be a better therapeutic option than targeting only one species. We also examine the dual inhibitors that target the amyloid proteins participating in the cross-seeding events. The future scopes and major challenges in understanding the mechanism and developing therapeutics are also considered. Detailed knowledge of the amyloid cross-seeding will stimulate further research in the practical aspects and better designing anti-amyloid therapeutics.